Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncology Physicians who Treat CID (US)

October 21, 2008
GVAX: Why did it fail? Let me list the possible ways......
By a GLG Expert Contributor
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer (pharmalive.com)
Cell Genesys is basically stopping work on GVAX inview of failure in two trials. The cause of the failure is not readily apparent.
October 15, 2008
Thyroid cancer: When it rains it pours
By a GLG Expert Contributor
Analysis of: Phase II Trial of Sorafenib in Advanced Thyroid Cancer (jco.ascopubs.org)
 as per an accompanying editorial "In conclusion, it is particularly gratifying that years of research in tumor biology and drug development have coalesced. Translation of these research advances into therapeutic benefits for patients with refractory thyroid cancer, and a related paradigm shift...
October 15, 2008
Genetically determined cancer therapy: It will be a wash.
By a GLG Expert Contributor
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs (online.wsj.com)
Genetic determinants will decrease use of some drugs due to mutations such as Kras which indicate less chance of response and thus the chemo agents will not be used.
October 8, 2008
Avastin/Tarceva/Roche/OSI/Genentech: So much for "synergy" in lung cancer
By a GLG Expert Contributor
Analysis of: Genentech Set Back by Cancer-Drug Study (online.wsj.com)
The primary goal was improved survival- NOT REACHED!!
October 6, 2008
Government Intervention is Here: Pharma had better get use to it....
By a GLG Expert Contributor
Analysis of: Roche Cuts Price of Cancer Drug (online.wsj.com)
"U.K. Health Service Agrees to Pay for Tarceva Following the Company's Discount" so that the price is equivalent to Taxotere.
October 3, 2008
Radon & Lung cancer: Outside of Uranium Mines is it Relevant???
By a GLG Expert Contributor
Analysis of: Protecting a Home From Silent Threat (www.nytimes.com)
Radon is responsible for about 15% on lung cancer deaths in the US??
October 2, 2008
Idera Pharma: is there room for another agent in recurrent renal cell ca??
By a GLG Expert Contributor
Analysis of: Idera Pharmaceuticals Announces Preliminary Data from Phase 2a Clinical Study of IMO-2055 Monotherapy in Renal Cell Carcinoma (www.pipelinereview.com)
Apparently Merck has an interest in this compound and it is in trial in combination in other neoplasms.
September 30, 2008
Epo & Stroke: The chickens coming home to roost.
By a GLG Expert Contributor
Analysis of: F.D.A. Reviewing Deaths in Anemia Drug Study (www.nytimes.com)
Epo (J & J's version) increased mortality when given to patients with a new stroke in an effort to improve brain function. What will this lead too?? 
September 29, 2008
Oh, Good, Not only won't seniors be able to understand it; they won't be able to afford it?
By a GLG Expert Contributor
Analysis of: Medicare Drug Premium on Rise (online.wsj.com)
Costs for Medicare part D are going up 31%
September 26, 2008
Molecular profiles in lung cancer: THE FUTURE IS HERE....
By a GLG Expert Contributor
Analysis of: Lung Cancer (content.nejm.org)
Clinical trials are being built around determining which molecular profiles require what therapy. It's here!!

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 512

Analytics


Generated at 2009-01-07T19:00:58.307